Home API Veliparib (IH)

Veliparib (IH)

Veliparib- Bulat Pharmaceutical

Enquire Now

[anr_nocaptcha g-recaptcha-response]

What is Veliparib?

Veliparib is a PARP (poly (ADP-ribose) polymerase) inhibitor used to treat cancer. It treats metastatic melanoma, NSCLC, prostate cancer, and brain tumors associated with primary metastatic tumors. Veliparib blocks a protein called PARP, thereby preventing the repair of the cancer cells and making them prone to anti-cancer drugs. Besides the above cancer type, Veliparib is still under evaluation for treating ovarian cancer.

Product Description

Molar Mass: 244.298

SMILES: C[C@]3(c2nc1c(C(N)=O)cccc1[nH]2)CCCN3

InChIKey: NAHVYVRKWKWKQ-CYBMUJFWSA-N

ALogP: 1.26

CAS Number: 912444-00-9

Chemical Formula: C13H16N4O

Form: Tablets

Solubility: DMF: 0.25 mg/ml, DMSO: 15 mg/ml, Ethanol: 0.1 mg/ml, PBS (pH 7.2): 10 mg/ml

Storage: -20°C

Suitable for: Adults

IUPAC Name: 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide

Veliparib

Approved Indications: 0

Experimental Indications: 108

As per clinical trials 1-4, the drug can be used in the following categories: 

  • Adenocarcinoma of the Lung (Phase 1/Phase 2)
  • Adrenal Gland Neoplasms (Phase 1)
  • Astrocytoma (Phase 2)
  • Bile Duct Neoplasms (Phase 1)
  • Brain Diseases (Phase 1)
  • Brain Neoplasms (Phase 2)
  • BRCA1 Protein (Phase 2)
  • Breast Neoplasms (Phase 3)
  • Breast Neoplasms, Male (Phase 1)
  • Brenner Tumor (Phase 1)
  • Burkitt Lymphoma (Phase 2)
  • Carcinoma (Phase 1)
  • Carcinoma, Hepatocellular (Phase 2)
  • Carcinoma, Merkel Cell (Phase 1)
  • Carcinoma, Neuroendocrine (Phase 1/Phase 2)
  • Carcinoma, Non-Small-Cell Lung (Phase 3)
  • Carcinoma, Renal Cell (Phase 1)
  • Carcinoma, Small Cell (Phase 1/Phase 2)
  • Carcinoma, Transitional Cell (Phase 1)
  • Central Nervous System Diseases (Phase 1)
  • Choroid Plexus Neoplasms (Phase 1)
  • Colonic Neoplasms (Phase 1)
  • Colorectal Neoplasms (Phase 2)
  • Craniopharyngioma (Phase 1)
  • Diffuse Intrinsic Pontine Glioma (Phase 1)
  • DNA Mismatch Repair (Phase 1)
  • Endometrial Neoplasms (Phase 1)
  • Ependymoma (Phase 1)
  • Esophageal Neoplasms (Phase 1)
  • Fallopian Tube Neoplasms (Phase 2)
  • Gallbladder Neoplasms (Phase 1)
  • Glioblastoma (Phase 2/Phase 3)
  • Glioma (Phase 2)
  • Gliosarcoma (Phase 2/Phase 3)
  • Hamartoma (Phase 2)
  • Hemangiosarcoma (Phase 2)
  • Hereditary Breast and Ovarian Cancer Syndrome (Phase 1)
  • Hodgkin Disease (Phase 2)
  • Intestinal Neoplasms (Phase 2)
  • Intraocular Lymphoma (Phase 1/Phase 2)
  • Leukemia (Phase 1)
  • Leukemia, Hairy Cell (Phase 2)
  • Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
  • Leukemia-Lymphoma, Adult T-Cell (Phase 2)
  • Leukemia, Monocytic, Acute (Phase 1)
  • Leukemia, Myeloid, Acute (Phase 2)
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)
  • Leukemia, Myelomonocytic, Acute (Phase 1)
  • Leukemia, Myelomonocytic, Chronic (Phase 2)
  • Liver Failure (Phase 1)
  • Liver Neoplasms (Phase 1)
  • Lung Neoplasms (Phase 2)
  • Lymphoma (Phase 2)
  • Lymphoma, B-Cell, Marginal Zone (Phase 2)
  • Lymphoma, Follicular (Phase 2)
  • Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
  • Lymphoma, Large-Cell, Immunoblastic (Phase 2)
  • Lymphoma, Mantle-Cell (Phase 2)
  • Lymphoma, Non-Hodgkin (Phase 2)
  • Lymphoma, T-Cell (Phase 2)
  • Lymphomatoid Granulomatosis (Phase 2)
  • Medulloblastoma (Phase 1)
  • Melanoma (Phase 2)
  • Meningioma (Phase 1)
  • Multiple Endocrine Neoplasia Type 1 (Phase 1)
  • Multiple Endocrine Neoplasia Type 2a (Phase 1)
  • Multiple Endocrine Neoplasia Type 2b (Phase 1)
  • Multiple Myeloma (Phase 2)
  • Mutation (Phase 2)
  • Myelodysplastic Syndromes (Phase 1)
  • Myeloproliferative Disorders (Phase 2)
  • Neoplasm Metastasis (Phase 1)
  • Neoplasms (Phase 2)
  • Neoplasms, Germ Cell, and Embryonal (Phase 1)
  • Nervous System Neoplasms (Phase 1)
  • Neuroectodermal Tumors (Phase 1)
  • Neuroectodermal Tumors, Primitive (Phase 1)
  • Neuroendocrine Tumors (Phase 1)
  • Oligodendroglioma (Phase 1)
  • Oropharyngeal Neoplasms (Phase 2)
  • Ovarian Diseases (Phase 1)
  • Ovarian Neoplasms (Phase 3)
  • Pancreatic Neoplasms (Phase 2)
  • Peritoneal Neoplasms (Phase 1)
  • Pheochromocytoma (Phase 1)
  • Polycythemia Vera (Phase 2)
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)
  • Primary Myelofibrosis (Phase 2)
  • Prostatic Neoplasms (Phase 2)
  • Prostatic Neoplasms, Castration-Resistant (Phase 2)
  • Renal Insufficiency (Phase 1)
  • Rhabdoid Tumor (Phase 1)
  • Sezary Syndrome (Phase 2)
  • Skin Neoplasms (Phase 2)
  • Small Cell Lung Carcinoma (Phase 2)
  • Spinal Cord Neoplasms (Phase 1)
  • Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
  • Stomach Neoplasms (Phase 1)
  • Testicular Neoplasms (Phase 2)
  • Thrombocythemia, Essential (Phase 2)
  • Thymoma (Phase 1)
  • Thyroid Neoplasms (Phase 1)
  • Triple-Negative Breast Neoplasms (Phase 3)
  • Urinary Bladder Neoplasms (Phase 1)
  • Uterine Cervical Neoplasms (Phase 2)
  • Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
  • Zollinger-Ellison Syndrome (Phase 1)

Clinical Trials:

FDA held a total of 102 trials for Veliparib in four phases. Fifty (50) organizations took part in these trials. 

Side Effects:

Major side effects observed after the consumption of Veliparib are:

  • Anemia
  • Nausea
  • Fatigue
  • Vomiting

Product CAS No

912444-00-9

Therapeutic Action

Veliparib (ABT-888) is a PARP inhibitor being investigated to treat non-small cell lung cancer, BRCA breast cancer, and ovarian cancer.

Conclusion

Veliparib is an anti-cancer drug that falls under the class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It kills cancer cells by eliminating the restructuring of their DNA and making them prone to anti-cancer drugs. Veliparib has a molar mass of 244.29 g/mol and is stored at room temperature. Some common side effects of this drug are vomiting, nausea, and fatigue. 

Enquire Now
close slider


[anr_nocaptcha g-recaptcha-response]




  • INQUIRY FORM

    INQUIRY FORM